✦ LIBER ✦

PUK14 Cost-Effectiveness Analysis of Mirabegron Versus Tolterodine Extended Release in the Treatment of Patients With Overactive Bladder in the United States

✍ Scribed by J. Xie; Z.Y. Zhou; C.N. Bui; Y. Yan; G. De; M.C. Runken; E.Q. Wu

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PUK10 Cost-Effectiveness Analysis of Sol

✍ W.M. Hart; V. Munro; P. Retsa 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

PUK21 Cost-Effectiveness Analysis of Sol

✍ W.M. Hart; J. Nazir 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 60 KB

The cost-effectiveness of solifenacin vs

✍ Linda Cardozo; Andrew Thorpe; Juliet Warner; Manpreet Sidhu 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 351 KB

THE COST-EFFECTIVENESS OF SOLIFENACIN VS

✍ Juliet L. Warner 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 80 KB

511 Effects of tolterodine extended rele

✍ P.F. Van Kerrebroeck; J. Wang; Z. Guan 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 202 KB

Symptom-specific efficacy of tolterodine

✍ V. ELINOFF; T. BAVENDAM; D. B. GLASSER; M. CARLSSON; N. EYLAND; R. ROBERTS 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB